We are live on ! Find out more

908 hedge funds and large institutions have $18.5B invested in Biogen in 2025 Q3 according to their latest regulatory filings, with 124 funds opening new positions, 323 increasing their positions, 269 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $573M | Put options by funds: $316M

70% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 73

20% more repeat investments, than reductions

Existing positions increased: 323 | Existing positions reduced: 269

13% more capital invested

Capital invested by funds: $16.3B → $18.5B (+$2.13B)

5% more funds holding

Funds holding: 866908 (+42)

0.77% more ownership

Funds ownership: 88.8%89.57% (+0.77%)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
908
Holders Change
+42
Holders Change %
+4.85%
% of All Funds
11.89%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
124
Increased
323
Reduced
269
Closed
73
Calls
$573M
Puts
$316M
Net Calls
+$257M
Net Calls Change
+$209M

BIIB Hedge Fund Activity: Q3 2025 in Review

908 of the 7,639 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2025, worth a combined $18.5B — up 13% from $16.3B a quarter earlier.

Buyers outnumbered sellers: 124 funds opened new BIIB positions and 73 closed out — a net gain of 51 holders — while 323 added to existing stakes and 269 trimmed.

The largest buyer was BlackRock, adding an estimated $163M. The largest seller was D.E. Shaw & Co, cutting an estimated $120M.

  • 908 institutional investors held Biogen (BIIB) as of Q3 2025, up from 866 in Q2 2025.
  • Funds reported $18.5B of Biogen stock for Q3 2025, up 13% quarter-over-quarter.
  • 124 funds opened new Biogen positions in Q3 2025 and 73 closed out, a net change of +51 holders.
  • The largest Biogen buyer in Q3 2025 was BlackRock, an estimated $163M added.
  • The largest Biogen seller in Q3 2025 was D.E. Shaw & Co, an estimated $120M sold.

Based on aggregated 13F filings for Q3 2025.